Retension Pharmaceuticals (NASDAQ:RTSN) Now Covered by Analysts at Zacks Research

by · The Markets Daily

Zacks Research assumed coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN – Get Free Report) in a report released on Wednesday, Zacks reports. The brokerage set a “hold” rating on the stock.

A number of other analysts have also issued reports on the stock. Guggenheim initiated coverage on shares of Retension Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $55.00 target price on the stock. Oppenheimer initiated coverage on Retension Pharmaceuticals in a report on Tuesday. They issued an “outperform” rating and a $50.00 price target for the company. Finally, Leerink Partners assumed coverage on Retension Pharmaceuticals in a report on Tuesday. They issued a “strong-buy” rating for the company. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Retension Pharmaceuticals has a consensus rating of “Buy” and an average price target of $52.50.

Get Our Latest Analysis on RTSN

Retension Pharmaceuticals Price Performance

Shares of NASDAQ RTSN opened at $10.72 on Wednesday. Retension Pharmaceuticals has a 12 month low of $9.66 and a 12 month high of $18.64.

Insider Activity at Retension Pharmaceuticals

In related news, Director Franklin M. Berger purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 13th. The stock was purchased at an average price of $12.00 per share, with a total value of $120,000.00. Following the completion of the transaction, the director owned 10,000 shares of the company’s stock, valued at approximately $120,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Eric L. Keller purchased 20,800 shares of the business’s stock in a transaction on Tuesday, October 13th. The shares were bought at an average cost of $12.00 per share, for a total transaction of $249,600.00. Following the purchase, the chief executive officer owned 423,377 shares of the company’s stock, valued at $5,080,524. This trade represents a 5.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

About Retension Pharmaceuticals

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.

Featured Articles